Antibody composition for detecting PD-1 receptor on lymphocyte surface and application thereof

Abstract

The invention provides an antibody composition for detecting a PD-1 receptor on the surface of lymphocyte and application of the antibody composition. The antibody composition for detecting the PD-1 receptor on the surface of lymphocyte comprises an anti-PD-1 antibody and any one or a combination of at least two of an anti-CD45 antibody, an anti-CD3 antibody, an anti-CD4 antibody and an anti-CD8 antibody. The invention also provides a kit for detecting the PD-1 receptor on the surface of the lymphocyte and a method for detecting the expression rate of the PD-1 receptor on the surface of the lymphocyte. The antibody composition for detecting the PD-1 receptor on the surface of the lymphocyte can be used for rapidly and accurately detecting PD-1 expression conditions of various types of lymphocytes in cooperation with flow cytometry, operation is easy, detection efficiency is high, continuous detection and dynamic observation of related samples are achieved, and a basis is provided for related drug treatment.

Description

technical field [0001] The invention belongs to the technical field of medical detection, and in particular relates to an antibody composition for detecting PD-1 receptors on the surface of lymphocytes and an application thereof. Background technique [0002] Programmed cell death protein-1 (PD-1) is a 50-55KD immunoglobulin superfamily type I transmembrane glycoprotein, which is a member of the CD28 superfamily and is mainly expressed in activated lymphoid cells. In cells and monocytes, it interacts with ligands PD-L1 / PD-L2 and participates in the suppression of immune responses in peripheral tissues. Under normal circumstances, the immune system will respond to foreign antigens accumulated in lymph nodes or spleen to promote the proliferation of antigen-specific T cells, while programmed cell death protein-1 (PD-1) and ligand PD-L1 / PD -L2 binding can transmit inhibitory signals, thereby inhibiting the proliferation of T cells. PD-1 molecule regulates the intensity and br...

AI Technical Summary

Problems solved by technology

[0003] According to the consensus of relevant experts at home and abroad, when the PD-1 / PD-L1 axis immune screening point inhibitor drugs are used in clinical practice, the detection of PD-L1 expression by immunohistochemical staining on tumor tissues is the preferred option for companion diagnosis. , but there are still many problems in its accuracy and standardized judgment

At the same time, the source of biopsy tissue samples is difficult, and the purpose of multiple detection and dynamic observation cannot be achieved

Images